Skip to main content
HALOZYME THERAPEUTICS, INC. logo

HALOZYME THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · HALO ISIN · US40637H1095 LEI · 529900242I3SV9AGM753 US Professional, scientific and technical activities
Filings indexed 1,022 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country US United States of America
Listing US HALO

About HALOZYME THERAPEUTICS, INC.

https://www.halozyme.com/

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on its proprietary ENHANZE® drug delivery technology. This platform is based on a recombinant human hyaluronidase enzyme (rHuPH20) that facilitates the subcutaneous delivery of injected drugs and fluids. The technology enables the conversion of intravenous therapies into subcutaneous formulations, which can reduce administration time and improve the patient experience. Halozyme licenses its ENHANZE® technology to pharmaceutical and biotechnology partners, allowing them to co-formulate their proprietary therapies for use across various therapeutic areas, with a significant focus on oncology.

Recent filings

Filing Released Lang Actions
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Regulatory Filings
2026-04-30 English
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Regulatory Filings
2026-04-24 English
SCHEDULE 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
Major Shareholding Notification
2026-03-27 English
3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
Director's Dealing
2026-03-23 English
ARS - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Annual Report
2026-03-23 English
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Director's Dealing
2026-02-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.